Evidence map›Paper›PMID 31002358›Full record

ArticleOncology reports2019

A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients.

Jingwei Dong, Mingjun Xu

Erratum issuedAbstract read
In one paragraph

Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jingwei DongDepartment of Anesthesiology, Beijing Obstetrics and Gynecology Hospital, Dongcheng, Beijing 100001, P.R. China.
Mingjun XuDepartment of Anesthesiology, Beijing Obstetrics and Gynecology Hospital, Dongcheng, Beijing 100001, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is the most common gynecologic malignancy with high incidence and mortality. The present study aimed to develop approaches for determining the recurrence type and identify potential miRNA markers for OC prognosis. The miRNA expression profile of OC (the training set, including 390 samples with recurrence information) was downloaded from The Cancer Genome Atlas database. The validation sets GSE25204 and GSE27290 were obtained from the Gene Expression Omnibus database. Prescreening of clinical factors was conducted using the survival package, and the differentially expressed miRNAs (DE‑miRNAs) were identified using the limma package. Using the Caret package, the optimal miRNA set was selected to build a Support Vector Machine (SVM) classifier. The miRNAs and clinical factors independently related to prognosis were analyzed using the survival package, and the risk score system was constructed. Finally, the miRNA‑target regulatory network was built by Cytoscape software, and enrichment analysis was performed. There were 46 DE‑miRNAs between the recurrent and non‑recurrent samples. After the optimal 19‑miRNA set was selected for constructing the SVM classifier, 6 DE‑miRNAs (miR‑193b, miR‑211, miR‑218, miR‑505, miR‑508 and miR‑514) independently related to prognosis were further extracted to build the risk score system. The neoplasm cancer status was independently correlated with the prognosis and conducted with stratified analysis. Additionally, the target genes in the regulatory network were enriched in the regulation of actin cytoskeleton and the TGF‑β signaling pathway. The 6‑miRNA signature may serve as a potential biomarker for OC prognosis, particularlyfor recurrence.

Indexed as

PrognosisComputational BiologyDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMicroRNAsMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsRisk FactorsSupport Vector MachineMicroRNAs

Identifiers

PMID31002358
PMCPMC6489015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.